These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. [Cystic fibrosis. Current indications for nebulized treatments: antibiotics and DNase]. Sardet-Frismand A. Rev Mal Respir; 1999 Jan 01; 16 Suppl 3():S131-2. PubMed ID: 10088286 [No Abstract] [Full Text] [Related]
27. Dornase alfa is well tolerated: data from the epidemiologic registry of cystic fibrosis. McKenzie SG, Chowdhury S, Strandvik B, Hodson ME, Investigators of the Epidemiologic Registry of Cystic Fibrosis. Pediatr Pulmonol; 2007 Oct 01; 42(10):928-37. PubMed ID: 17726701 [Abstract] [Full Text] [Related]
39. Effect of smaller droplet size of dornase alfa on lung function in mild cystic fibrosis. Dornase Alfa Nebulizer Group. Geller DE, Eigen H, Fiel SB, Clark A, Lamarre AP, Johnson CA, Konstan MW. Pediatr Pulmonol; 1998 Feb 01; 25(2):83-7. PubMed ID: 9516090 [Abstract] [Full Text] [Related]
40. The use of dornase alfa in patients with COVID-19. Ramachandram DS, Kow CS, Hasan SS. J Cyst Fibros; 2023 May 01; 22(3):580. PubMed ID: 36966036 [No Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]